China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary Shuanghe Huali passed a compliance inspection for good manufacturing practices.
The inspection was conducted by the Henan Provincial Medical Products Administration on Shuanghe Huali's production site at 369 Qinggong Road in China's Henan province. The products inspected included glucose, sodium chloride, and glucose-sodium chloride injections.
Shares of the pharmaceutical company closed 3% higher Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.